Introduction {#Sec1}
============

It was shown that diagnostic methods for ovarian cancer early-stage detection are ineffective \[[@CR1]\]. Intensive screening tests in groups with the highest risk of ovarian cancer, such as carriers of the *BRCA1* and *BRCA2* mutations, have also low efficacy \[[@CR1]--[@CR6]\]. For these reasons, patients who are carriers of the *BRCA1/2* mutation are offered risk-reducing salpingo-oophorectomies (RRSO), which is widely accepted by *BRCA1/2* carriers and have been performed for decades in hospitals and gynecological clinics all around the world. At the moment, such management is considered the best possible option for reducing ovarian cancer risk and improving the survival rate \[[@CR1], [@CR7], [@CR8]\]. However, after this surgery, there remains a risk of breast cancer and risk of peritoneal cancer. Data about characteristics of these cancers developing after RRSO are pure. In this study, we analyzed characteristics of breast or peritoneal cancer after RRSO. Follow-up was conducted over the course of 12 years. The analysis included: age at cancer diagnosis, time from RRSO to the diagnosis of cancer, significance of *BRCA1* mutation type in patients diagnosed with breast or peritoneal cancer during postoperative follow-up.

Material and methods {#Sec2}
====================

The material comprised of 195 *BRCA1* carriers from the West Pomeranian Voivodship in Poland who performed RRSO between 15.09.1999--31.12.2012 at the Department of Gynecological Surgery and Oncology of Adults and Adolescents of the Pomeranian Medical University in Szczecin. No malignancy was found in the histopathological examination of the excised material. 80 of 195 (41.03%) patients were treated for breast cancer before risk-reducing surgery. All patients carried one of three *BRCA1* mutations most commonly occurring in the Polish population (c.5266dupC -- 128 patients, c.4035delA -- 19 patients and c.181T \> G -- 48 patients) \[[@CR9]\]. Median follow-up time for the group of 195 patients amounted to 80 months.

At the time of observation 16 out of 195 patients were diagnosed with cancer. 6 (3.1%) cases with primary breast cancer (PBC); 3 (1.5%) cases contralateral primary breast cancer (CPBC); 5 (2.56%) cases with cancer cells diagnosed in a scar after mastectomy defined as relapse of breast cancer (RBC); 2 (1.03%) cases with peritoneal cancer. The detailed characteristics of 16 patients from the study group are shown in Table [1](#Tab1){ref-type="table"}. Ten (62.5%) of these patients had been treated for breast cancer also before the RRSO. The median age of affected patients (*n* = 16) at the time of RRSO was 46.5 years (36--63 years), which did not deviate from median age for the whole group (*n* = 195) -- 47 years (31--78 years).Table 1Characteristics of 16 patients who developed cancer after risk-reducing salpingo-oophorectomyPatient numberBRCA1 mutation typeCancer diagnosed before prophylactic surgery (yes/no) locationDate of prophylactic surgery (month/year)Date of cancer diagnosis after prophylactic surgery (month/year)Cancer diagnosed after prophylactic surgery (location)Time from risk-reducing surgery to cancer diagnosis (months)1.c.5266dupCYes breast02/200806/2008breast - second primary42.c.5266dupCYes breast06/200604/2008breast -recurrence223.c.181T \> GYes breast09/199911/2004peritoneum624.c.5266dupCYes breast11/200205/2004breast -recurrence185.c.181T \> GYes breast02/200108/2003peritoneum306.c.5266dupCYes breast01/200204/2008breast -recurrence757.c.181T \> Gno08/200306/2008breast - primary588.c.5266dupCno06/200210/2006breast - primary529.c.5266dupCYes breast09/200101/2002breast -recurrence410.c.5266dupCno11/200101/2008breast - primary7411.c.5266dupCno04/200603/2008breast - primary2312.c.5266dupCYes breast06/200406/2006breast - second primary2413.c.4035delAno11/200207/2009breast primary8014.c.181T \> GYes breast05/200009/2012breast - second primary14815.c.5266dupCYes breast07/200203/2003breast -recurrence816.c.5266dupCno11/200006/2003breast - primary31

Histopathological examination of tissues excised during RRSO was performed with extraordinary caution in order to rule out the presence of cancerous foci in the ovary or the salpinx, which have been described in the literature and could have been missed in the primary histopathological assessment \[[@CR10], [@CR11]\]. Repeated histopathological examination of excised material failed to reveal micro-invasive foci in both of our patients diagnosed with primary peritoneal cancer during the follow-up period.

The patient analysis included: age at cancer diagnosis, time from RRSO to the diagnosis of cancer, significance of *BRCA1* mutation type in patients diagnosed with breast or peritoneal cancer during postoperative follow-up. The data has been subjected to statistical analysis.

Statistical analysis {#Sec3}
--------------------

All variables were checked for normal distribution using the Shapiro-Wilk test. They were described as means, standard deviations, medians, quartiles, as well as minimal and maximal values. We checked for statistically significant differences in quantitative variables using Student's t-test or Mann-Whitney test and Fisher's exact test were used in order to calculate differences in proportions. For all tests, the differences were considered statistically significant at *p*-value \< 0.05. Statistical analyses were performed using STATA 11 software (license no. 30110532736).

Results {#Sec4}
=======

Summary of selected features of *BRCA1* carriers diagnosed with cancer during the follow-up period is shown in Table [2](#Tab2){ref-type="table"}. The mean age of cancer diagnosis in 16 patients who were subject of the study, was 53.19. Peritoneal cancer observed in two patients was diagnosed significantly later at a mean age of 60. Both patients were previously treated (before RRSO) due to breast cancer. With regards to breast cancer, the PBC was diagnosed in 6, CPBC in 3 and RBC in 5 out of 16 cases. The peritoneal cancer was diagnosed almost 7 months earlier than PBC (46 months vs. 53 months), but this difference was not statistically significant. Breast cancer recurrence was diagnosed almost twice as fast as primary breast cancer and peritoneal cancer (25.4 vs. 53 months), but this difference was also not statistically significant.Table 2Summary of selected features of *BRCA1* carriers diagnosed with cancer during the follow-up periodType and numberPeritoneal cancer\
*n* = 2Primary breast cancer\
*n* = 6Contralateral breast cancer\
*n* = 3Breast cancer recurrence\
*n* = 5Total for the whole group diagnosed with cancers\
*n* = 16Feature and type of mutationPatient age at the time of cancer diagnosis (mean; years old)6050.0058.6751.0053.19Time from RRSO to cancer diagnosis (mean; months)465358.6725.444,56Type of BRCA1 mutation in patients who developed cancer during follow-up period2x c.181T \> G4x c.5266dupC 1x c.181T \> G 1x c.4035delA2x c.5266dupC 1x c.181T \> G5x c.5266dupC11x c.5266dupC 4x c.181T \> G 1x c.4035delA

Peritoneal cancers diagnosed during the follow-up period were observed only in two c.181T \> G BRCA1 mutation carriers. We performed a statistical analysis of the frequency of peritoneal cancer in c.181T \> G BRCA1 mutation carriers in comparison to other mutation carriers. Statistical significant differences were observed for this characteristic (*p* = 0.0392; OR = 29.00; 95% CI: 1.048--802.64).

The time to any cancer diagnosis after RRSO was significantly shorter for c.5266dupC mutation carriers compared to c.181T \> G and c.4035delA mutation carriers (30.45 vs. 75.6 months; *p* = 0.021).

The c.5266dupC *BRCA1* mutation was most frequent among patients who developed any cancer -- 68.75% (11/16), followed by c.181T \> G mutation -- 25% (4/16), and c.4035delA observed in 6,25% (1/16) of patients. This reflects the frequency of these mutations in the Polish population.

Discussion {#Sec5}
==========

In our material, we observed relatively advanced age of cancer diagnosis among *BRCA1* carriers after RRSO. It is most likely associated with particularly late age of undergoing this surgery. In our study, the average age of undergoing such an operation is 46--49 years \[[@CR12]--[@CR14]\]. The reason for delayed RRSO was that, in a significant number of breast cancer patients, *BRCA1* mutation was diagnosed after diagnosis of breast cancer. In our study group, 62.5% of patients had been previously treated due to breast cancer. As indicated in our previous studies, patients treated for breast cancer undergo RRSO at a later age compared to patients without the diagnosis of breast cancer (50 vs. 46 years; *p* = 0.0003) \[[@CR13]\].

In our study, we found that the mean age at diagnosis of any breast cancer was similar to those observed by Ramon et al. and equaled 52.2 vs. 51.8 years of age. The mean time from RRSO to diagnosis of breast cancer was also similar and amounted to 44,35 vs. 40.8 months \[[@CR15]\]. Fakkert et al. reported breast cancer diagnosis among *BRCA1* patients after RRSO at a significantly younger age -- 45.25 years, and somewhat longer time from RRSO to the diagnosis of breast cancer -- 52.8 months \[[@CR16]\]. Kauff et al. indicated significantly shorter time to diagnosis of breast and peritoneal cancer among patients after RRSO -- 10.3 and 16.3 months, respectively \[[@CR17]\].

Finch et al. showed that mean time to development of peritoneal cancer among *BRCA1* carriers after RRSO amounted to 63.6 months, although they emphasize that in three cases the diagnosis was made before the end of three years. The mean age of those patients at the time of diagnosis equalled 51.5 years \[[@CR18]\], which approximates our data. In another study, Finch et al. reported similar mean age at diagnosis of peritoneal cancer - 51.6 years, but the mean time to diagnosis extended to 73.2 months. Possibly, prolonged time to the diagnosis of peritoneal cancer might have been influenced by the inclusion of four patients with *BRCA2* mutation into the study group of 32 patients \[[@CR19]\]. In case of particularly short time to diagnosis of peritoneal cancer after RRSO, one should very carefully assess the excised material in order to rule out micro-invasive foci, which is described in the literature \[[@CR10], [@CR11]\].

Rhiem et al. observed a case of peritoneal cancer in a 57-year-old woman 26.4 months after RRSO \[[@CR20]\]. Rebbeck et al. diagnosed peritoneal cancer in patients 45.6 and 103.2 months after RRSO \[[@CR21]\]. Kiely et al. showed peritoneal cancer in a 70-year-old patient eight 96 months after RRSO \[[@CR22]\]. In another publication, Kauff et al. reported peritoneal cancers among patients after RRSO on average after 41.16 months and breast cancers after 36.36 months \[[@CR23]\]. Powell et al. demonstrated equally short time of diagnosis of peritoneal cancer in a patient after RRSO as Kauff \[[@CR17]\]. The diagnosis was made as early as a year after the procedure \[[@CR24]\]. In our material, the mean age of patients diagnosed with peritoneal cancer was 60 and the mean time from RRSO to the diagnosis of peritoneal cancer amounted to 46 months.

Influence of particular *BRCA1* gene mutation on studied characteristics is a very difficult topic to discuss. Although c.5266dupC*,* the most common mutation in the Polish population, is also often identified in the Ashkenazi Jewish population \[[@CR25]\], available literature lacks data for discussion. The frequency of particular *BRCA1* mutations observed between carriers who were diagnosed with any cancer reflects the frequency of these mutations in the Polish population. However, we found peritoneal cancer in two *BRCA1* carriers with c.181T \> G mutation, only. These two patients also developed breast cancer before RRSO. We observed that the time to any cancer diagnosis after RRSO was significantly shorter for c.5266dupC *BRCA1* mutation carriers. We think that these are interesting observations important for future analyses on significance of particular *BRCA1* gene mutation, however, for more general conclusions studies on larger groups should be performed.

Conclusions {#Sec6}
===========

The mean age of cancer diagnosis and the mean time periods from RRSO to the diagnosis of cancer are similar to those observed by other researchers. The carriers of c.181T \> G and c.5266dupC *BRCA1* mutation should be the subject further studies in context of breast and peritoneal cancer risk or time of cancer development after RRSO, respectively.
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